A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).

Inclusion Criteria:

• Body weight 40 kg--150 kg
• Chest radiograph with no evidence of clinically significant abnormality
• Uncontrolled asthma

Exclusion Criteria:

• Asthma exacerbation during screening
• Known malignancy
• Known immunodeficiency
• Pre-existing lung disease other than asthma
• Uncontrolled clinically significant medical disease
• Current smoker
• History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator
• Prior allergic reaction to a monoclonal antibody
• Patients (men and women) of reproductive potential who are not willing to use contraception
• Pregnancy